All Stories

  1. Feature Reviews in Cardiovascular Diseases
  2. Aging of the vascular system: proposal of preventive intervention with known natural substances
  3. COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues
  4. Insulin Resistance with Associated Hyperinsulinemia as a Cause of the Development and Worsening of Heart Failure
  5. Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
  6. Chronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
  7. Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long
  8. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction
  9. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
  10. A case of adverse reaction to booster dose of COVID-19 vaccination: could D-dimer elevation suggest increased clotting risk?
  11. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment
  12. Editorial: Methods in general cardiovascular medicine
  13. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
  14. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
  15. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview
  16. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
  17. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between Novembe...
  18. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
  19. Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19)
  20. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
  21. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial
  22. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension
  23. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”
  24. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension
  25. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature
  26. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome
  27. Reply:
  28. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
  29. Insulin resistance: Is it time for primary prevention?
  30. The Importance of Tricuspid Regurgitation and Right Ventricular Overload in ICD/CRT Recipients: Beside the Left, beyond the Left
  31. Endocrine Alterations Are the Main Determinants of Cardiac Remodelling in Restrictive Anorexia Nervosa
  32. A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
  33. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
  34. Letter by Fazio and Carlomagno Regarding Article, “Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population”
  35. Thyroid Hormones and Cardiovascular System: From Bench to Bedside
  36. Late Onset of Hypoxemia Due to a Pulmonary Arteriovenous Malformation During Selective Estrogen Receptor Modulator Therapy
  37. Cardiovascular and metabolic effects of Berberine
  38. Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
  39. Long term combination treatment for severe idiopathic pulmonary arterial hypertension
  40. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation
  41. Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction
  42. The GH/IGF-1 Axis and Heart Failure
  43. Myocarditis and dilated cardiomyopathy: possible connections and treatments
  44. Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure
  45. Prehypertension and Elevated Risk of Cardiovascular Disease: Physiopathologic Mechanisms
  46. Association between post-ischemic forearm blood flow and blood pressure response to maximal exercise in well trained healthy young men
  47. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension
  48. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men
  49. Tadalafil in Primary Pulmonary Arterial Hypertension
  50. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning par...
  51. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade
  52. Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men
  53. Effects of Thyroid Hormone on the Cardiovascular System
  54. Hyperthyroidism, Subclinical
  55. Subclinical Hypothyroidism and Cardiovascular Risk
  56. Subclinical Thyroid Dysfunction and the Heart
  57. Reactive hyperemia and cardiovascular performance in athletes regularly trained
  58. Prospective Evaluation of Hypertensive Patients with Carotid Kinking and Coiling: An Ultrasonographic 7-Year Study
  59. Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer
  60. The importance of using strict inclusion criteria in subclinical hypothyroid studies
  61. Effects of Subclinical Thyroid Dysfunction on the Heart
  62. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
  63. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
  64. Subclinical Hypothyroidism and Cardiac Function
  65. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  66. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  67. Mortality in elderly patients with subclinical hyperthyroidism
  68. Growth hormone corrects vascular dysfunction in patients with chronic heart failure
  69. Impact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
  70. Does the Growth Factor Approach Have a Future in the Treatment of Human Heart failure?
  71. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients*
  72. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients
  73. Growth hormone and cardiac function
  74. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence
  75. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  76. Heart Failure: Potential Benefit of Growth Hormone Therapy
  77. A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
  78. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  79. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  80. Growth Hormone and the Heart
  81. Growth hormone as a potential future therapy for congestive heart failure
  82. Growth Hormone in Heart Failure
  83. Cardiac Effects of Growth Hormone in Physiology and in Heart Failure
  84. Doxorubicin‐induced cardiomyopathy treated with carvedilol
  85. Reentrant Atrioventricular Nodal Tachycardia Induced by Levothyroxine
  86. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
  87. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  88. Prevalence of Carotid Kinking and Coiling in a Population at Risk
  89. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
  90. Cardiovascular aspects in acromegaly: Effects of treatment
  91. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
  92. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
  93. Cardiac performance: Growth hormone enters the race
  94. Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency
  95. Optimal determination of right ventricular filling dynamics in systemic hypertension
  96. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta- blockade
  97. Pacemaker Malfunction Due to Subcutaneous Emphysema
  98. Growth Hormone and the Heart
  99. Growth hormone and the heart
  100. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
  101. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
  102. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
  103. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
  104. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
  105. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
  106. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
  107. Platelet Aggregability in Patients with a VVI Pacemaker
  108. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study
  109. Capillary Blood Flow to the Skin of Forearm in Cirrhosis
  110. Influence of atenolol on the relationship between heart rate and qt interval in patients with exercise‐induced myocardial ischemia
  111. Pacemaker Malfunction Due to Subcutaneous Emphysema — A Case Report
  112. Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart
  113. Follow‐Up of a Respiratory Rate Modulated Pacemaker
  114. Fourier Analysis in Patients with Different Pacing Modes
  115. Efficacy of Ticlopidine in the Prevention of Thromboembolic Events in Patients with VVI Pacemakers
  116. Cardiac function and sympathetic activity in young diabetics
  117. A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer
  118. Atenolol and Amiodarone: A Comparative Study of Their Anti-Ischaemic Effect
  119. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil
  120. Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study
  121. Obesity and cardiac function.